Begin main content
CADTH Document Viewer

Programs for the Treatment of Opioid Addiction: An Environmental Scan

September 2019

Abbreviations

  • AFM — Addictions Foundation Manitoba
  • DSMV — Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
  • DTC — drug treatment courts
  • ED — emergency department
  • HMP — Her Majesty's Penitentiary
  • ISKM — Information Services and Knowledge Mobilization
  • LHIN — Local Health Integration Networks
  • MAT — medication-assisted treatment
  • MATICCE — MAT Implementation in Community Correctional Environments
  • MMT — methadone maintenance treatment
  • NL — Newfoundland and Labrador
  • OAT — opioid agonist therapy
  • OTC — opioid treatment centre
  • OTP — opioid treatment program
  • RAAM — Rapid Access to Addictions Medicine
  • SAMHSA — Substance Abuse and Mental Health Services Administration
  • WMS — Withdrawal Management Services

Summary

  • A literature search and a survey informed this Environmental Scan. Survey respondents were comprised of stakeholders involved in health care for patients with opioid addiction.
  • There are numerous types of opioid programs both in Canada and internationally, including residential treatment, community treatment, primary care, pharmacy treatment, therapeutic communities, and programs within correctional settings.
  • Ideally, patients would be seen with no wait times and be accepted into treatment immediately. According to survey results, wait times in Canada vary from immediate service to about three months.
  • Facilitators to timely access include walk-in style programming, transportation initiatives, increased staffing, lowered stigma, flexible appointment times, and integrated treatment services. Telehealth programs are also successful in facilitating access to opioid programming across Canada, especially in rural and remote regions.
  • Most services appear to accept patients who have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)-diagnosed substance use disorder, with not many other restrictions. Common prioritization criteria for services include patients who are at high risk, such as pregnant patients, adolescents, and individuals with HIV.
  • Communication and integration of services was noted as key to improving transitions between settings, including from the emergency department (ED) to primary care, primary care to specialized clinics, and from correctional settings to the community.

Context

Opioids are a class of drugs that provide pain-relieving properties and often a sense of euphoria. Opioids can be obtained through a prescription (such as codeine, fentanyl, morphine, oxycodone, and hydromorphone) or illegally (such as heroin).1 Substance abuse and opioid addiction occur when an individual misuses opioids in a problematic way, such as when incorrect dosages of opioids are taken or prescriptions are misused.2 Often, this is accompanied by the four “C’s” of addiction:

  • cravings
  • a loss of control of amount or frequency of use
  • compulsion to continue using
  • use despite negative consequences.2

Canada consumes the second-highest number of opioid products per capita, with only the US consuming more.3 Over-prescribing and consumption of opioids, paired with the addictive nature of the drug, has led to high rates of opioid misuse, addiction, and overdose. Between January 2016 and September 2018, more than 10,300 apparent opioid-related deaths occurred in Canada, with a large percentage (more than 90%) of these deaths being accidental.4

Treatments for opioid addiction include pharmacological treatments and non-pharmacological treatments. Pharmacological treatments include opioid agonist therapy (OAT) — a prescribed treatment of an opioid agonist such as methadone or buprenorphine/naloxone. These agonists must be taken daily; they prevent withdrawal but do not produce the euphoric high of other opioids.5 Non-pharmacological treatments include counselling, psychological therapies (such as cognitive behavioural therapy), and psychosocial support.6 Other harms reduction strategies can be used to lessen the negative consequences of opioid use, such as safe injection sites and naloxone kits.7 However, in Canada, limited availability of specialized treatment services and the rising demand for intervention limits accessibility.8 While guidance and inventories of programs are available, there is interest in understanding the front-line practices and approaches to providing care for individuals with opioid addiction. Some of these practices may influence policies or programs that jurisdictions choose to implement, or practices within existing programs. There is specific interest in program availability and wait times, as well as best practices for supporting patients in receiving OAT through care setting transitions. There is a need to gain perspective on the current context of use of different programs and practices for opioid addiction, and a better understanding of the movement of patients through the system.

To support these needs, CADTH conducted an Environmental Scan to gain direct stakeholder perspectives on the current context surrounding opioid addiction programs (including both OADs and other non-pharmacological programming) and care setting transitions. For the purposes of this report, opioid substitution therapy is referred to as OAT. OAT includes methadone and Suboxone (buprenorphine/naloxone) therapies. Suboxone is buprenorphine combined with naloxone (equivalent to buprenorphine/naloxone). Opioid addiction refers to an addiction to any form of opioids, including illicit opioids such as heroin, and prescription opioids such as oxycodone. For the purposes of this report, opioid addiction also encompasses opioid use disorder and substance use disorder related to opioids. In this report, OAT includes both pharmacological treatment and non-pharmacological treatment.

Objectives

The key objectives of this Environmental Scan are as follows:

  • Describe the opioid addiction treatment programs that are currently available for use in Canada and internationally.
  • Identify the recommended wait times for opioid addiction treatment programs in Canada.
  • Summarize the factors influencing wait times for opioid addiction treatment programs in Canada.
  • Identify the patient characteristics or prioritization criteria in use for determining entry to opioid addiction treatment programs in Canada.
  • Describe current practice as it relates to supporting patients receiving opioid agonist therapy through care setting transitions.

This Environmental Scan does not include an assessment of the clinical or cost-effectiveness of opioid addiction treatment programs. Thus, conclusions or recommendations about the value of these programs are outside the scope of this report. For more information on intervention effectiveness, the Canadian Research Initiative in Substance Misuse published a national guideline concerning the clinical management of opioid addiction, including a review of pharmacological and non-pharmacological treatments.9 CADTH has also published an Evidence Bundle with information on prescription opioid abuse prevention and treatment.10

This Environmental Scan does not endorse one form of OAT over others, nor is it a comprehensive list of all available types of addiction programming, forms of treatment, or settings of treatment.

Methods

This Environmental Scan is based on a limited literature search combined with a survey (Appendix 1)distributed to identified relevant stakeholders across Canada.

This Environmental Scan is based on a limited literature search. Relevant published literature was identified primarily through a targeted MEDLINE search; grey literature was retrieved through a focused Internet search. The literature search was limited to English-language documents published between January 01, 2013, and November 29, 2018. Citations retrieved before May 9, 2019 were incorporated into the report. Table 1 outlines the criteria used for information gathering and screening.

Research Questions

The literature review attempted to address the following questions through the literature search:

  1. What opioid addiction treatment programs are currently available for use in Canada for individuals with substance abuse problems?
  2. What opioid addiction treatment programs are currently available for use internationally for individuals with substance abuse problems?
  3. What are the recommended wait times for individuals entering opioid addition treatment centres or programs?
  4. What are the facilitators and barriers to timely access to opioid treatment centres or programs?
  5. What are the prioritization and patient selection criteria used to determine entry of individuals into opioid treatment centres or programs in Canada?

For patients receiving opioid addiction treatment and are transitioning through different care settings, what are the current policies, practices, and guidelines?

Table 1: Components for Literature Screening and Information Gathering

Population Patients with opioid use disorder (other names: opioid addiction, substance use disorder, opioid abuse disorder)
Intervention Opioid addiction treatment programs including:
  • OAT or pharmacological (e.g., methadone [Methadose] or buprenorphine [Suboxone] therapy, clonidine) treatment programs
  • other opioid addiction/disorder treatment programs (e.g., psychological, risk-reduction, multimodal approaches)
Settings Any setting (community, in-patient, acute care)Settings of interest:
  • correctional settings (e.g., probationary settings, prison settings, bail supervisory settings, parole settings, alternative measures programs, etc.)
  • transitionary settings (i.e., supporting patients on OAT who are transitioning between care settings such as from an emergency department or correctional facility to a specialty OAT clinic or primary care, etc.)
Types of Information RQ1: Inventories of opioid addiction treatment programs within Canada
RQ2: Inventories of opioid addiction treatment programs internationally (countries)
RQ3: Recommended wait times for entry into opioid addiction treatment program
RQ4: Facilitators and barriers to timely access and availability of opioid addiction programs
RQ5: Criteria for entry into opioid addiction treatment programs;
prioritization structure and criteria for patients entering or on wait lists for opioid addiction treatment
RQ6: Policies, practices, or guidelines for transitioning clients between care settings (see Settings in this table).

OAT = opioid agonist therapy; RQ = research question.

Screening and Study Selection

One author independently screened titles and abstracts for eligibility according to the inclusion criteria outlined in Table 1. Articles that were published in a language other than English or French, or were published prior to January 1, 2013, were excluded. For research questions 1 and 2, the following types of publications were excluded: reports that were not a review or summary (i.e., were randomized controlled trials, cohort studies, etc.) or were not inventories or summaries of opioid addiction programs (i.e., focused on one addiction program or focused on non-opioid substance abuse).

For research questions 3, 4, 5, and 6, there were no limitations on publication type, except conference abstracts, which were ineligible.

Survey

A survey was conducted to address the objectives of this Environmental Scan. The survey was distributed electronically using SurveyMonkey (www.surveymonkey.com) to key jurisdictional informants and stakeholders involved in research, planning, management, and service provision related to opioid addiction treatment in Canada. Survey respondents were identified through CADTH’s Implementation Support and Knowledge Mobilization (ISKM) team networks, and other available networks via stakeholder and expert suggestions.

The electronic surveys were distributed to stakeholders in March of 2019 via email invitation. The survey targeted the following categories of respondents:

  • health care providers, in various care settings, involved in OAT including providers of direct front-line care to patients with opioid addiction
  • policy-makers involved in policy development for the care of patients with opioid addiction
  • clinical decision-makers involved in program or practice development for the care of patients with opioid addiction; Subgroups of interest were respondents with a Correctional Service perspective.

The survey consisted of 22 questions, including questions regarding demographics, wait times, barriers, and facilitators to timely access, prioritization of patients, and support of patients across care settings. A full list of questions is provided in Appendix 1.

The survey questions were reviewed by external stakeholders and piloted within SurveyMonkey by independent CADTH researchers who were not involved with the project.

Synthesis Approach

Feedback from respondents who gave consent to use their survey and consultation information were included in the report. Survey responses were excluded if all answers (other than demographics) were blank, the respondent refused participation, or if consent to use information was not provided.

Responses were analyzed by the objectives of this Environmental Scan, then by organization and jurisdiction. In the case of multiple responses from one organization, all responses were included. Quantitative and multiple choice answers were summarized through tables by organization and presented narratively. Qualitative (or open-ended) answers were categorized using thematic analysis and were also presented narratively and in tables.

Findings from the literature search were presented separately from survey results and were summarized narratively. When summarizing the available addiction programs internationally, countries were chosen based on similarities to the Canadian context (e.g., prevalence of opioid misuse, type of health care system, population characteristics, and gross domestic product [GDP], and on the depth of information available).

Feedback from respondents who gave consent to use their survey and consultation information were included in the report. Survey responses were excluded if all answers (other than demographics) were blank, the respondent refused participation, or if consent to use information was not provided.

Responses were analyzed by the objectives of this Environmental Scan, then by organization and jurisdiction. In the case of multiple responses from one organization, all responses were included. Quantitative and multiple choice answers were summarized through tables by organization and presented narratively. Qualitative (or open-ended) answers were categorized using thematic analysis and were also presented narratively and in tables.

Findings from the literature search were presented separately from survey results and were summarized narratively. When summarizing the available addiction programs internationally, countries were chosen based on similarities to the Canadian context (e.g., prevalence of opioid misuse, type of health care system, population characteristics, and gross domestic product [GDP], and on the depth of information available).

Findings

The findings presented are based on survey and literature results. The survey was distributed to 72 stakeholders representing all Canadian provinces and territories. Nineteen total survey responses were received and 10 jurisdictions responded to the survey, including Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador (NL), the Northwest Territories, Nova Scotia, Ontario, Prince Edward Island, and Yukon. Appendix 2 describes survey respondents and the organizations represented.

The literature searches yielded 1,119 citations, of which 36 studies were determined to be eligible to address the research questions. Fifteen articles were published in Canada, seven articles were published in the US, five articles were published in Australia, one was published in New Zealand, two articles were published in France, one was published in Spain, one was published in Sweden, one was published in Switzerland, and one was published in the UK. Two articles focused on European countries in general. For additional information, grey literature — including government websites and program websites — were also included.

Objective 1: Opioid addiction treatment programs currently available for use in Canada and internationally

This objective was addressed by research questions 1 and 2 based on findings from the literature. More information on specific programs can be found in Appendix 3, Appendix 4, and Appendix 5.

The most commonly cited type of opioid addiction treatment program was OAT. This includes methadone and Suboxone (buprenorphine/naloxone). The following programs are not an exhaustive list of all possible opioid programming available in each province or country.

Some provinces include a directory of programming available in their jurisdictions. For example, The Government of Saskatchewan publishes a Directory of Mental Health and Addictions Services in Saskatchewan.11 The Regional Health Authorities of New Brunswick publish a list of addictions and mental health services on their health networks Horizon and Vitalité.

Canada

Each province and territory has individual OAT programs that have different policies and practices.12 The biggest expansion in opioid treatment has occurred in British Columbia and Ontario, although other provinces are starting to expand programs to meet the increasing demand.12

In Canada, treatment is generally provided at a clinic, a physician’s office, or at a pharmacy. Family physicians and psychiatrists provide the majority of OAT and previously could prescribe methadone if they obtained an exemption under Section 56 of the Controlled Drugs and Substances Act. As of May 19, 2018, physicians no longer require this exemption.13 In a primary care setting, OAT is generally provided in:

  • provincially funded addiction programming clinics, with comprehensive services over a variety of disciplines
  • a physician’s office, subsidized by a provincial funding stream
  • in federal or provincial correctional facilities.

Indigenous Services Canada provides methadone for First Nation, Métis, and Inuit patients.

Multidisciplinary Treatment (Pharmacotherapies and Psychosocial Therapies)

Programs in Canada are usually multidisciplinary in nature, often combing both pharmacotherapies and psychosocial therapy. In British Columbia, the College of Physicians and Surgeons of British Columbia requires simultaneous treatment of mental health and addictions.12 In Saskatchewan, physicians supplying methadone maintenance treatment (MMT) must also refer patients to addiction counsellors.11 The Methadone Maintenance Treatment Handbook from the College of Physicians and Surgeons of Nova Scotia suggests that all MMT programs should include collaborative treatment, including counselling and case management.14

One of the major providers of addiction services in Manitoba, Addictions Foundation of Manitoba (AFM), runs the Manitoba Opioid Support and Treatment program in Winnipeg and Brandon. This program combines counselling, education, needle exchanges, and linkages with other community supports. AFM also runs a program called the Methadone Intervention and Needle Exchange Program, based on a harms reduction strategy. The program has a team-based approach with a physician and nurse, as well as a needle exchange program, an on-site dispensary, group meetings, traditional healing, and psychosocial supports. In St. John’s, NL, there is the Opioid Treatment Centre, which serves the Eastern Region of NL.15 It is a multidisciplinary outpatient program that has no set length of treatment but encourages treatment for at least one year.16

Pharmacotherapies

In British Columbia, methadone historically has been the standard of care and in 2016, 80% of individuals in medication-assisted treatment (MAT) were using methadone as their form of OAT.17 All four Atlantic provinces have provincially funded methadone programs.12 To prescribe methadone, many physicians require special approval or exemptions. For example, in Alberta, the College of Physicians & Surgeons of Alberta (CPSA) oversees the guidelines surrounding OAT and approves physician prescribing of OAT.12,18 In Ontario, methadone is dispensed in a liquid formulation and patients initiating treatment will often receive their medication at a specialized addiction clinic, under observation. After stabilization, patients will then receive their treatment through a family physician or community pharmacy.19 Ontario and NL also allow nurse practitioners to administer treatment, in addition to physicians, 7,15 to combat the lack of physicians available to prescribe treatment.15 NL has had an established methadone program since 2005 but currently only has seven physicians for more than 1,000 patients (with 14 physicians in total with an exemption to prescribe methadone and/or Suboxone).12,15

Buprenorphine/naloxone is also used as a pharmacotherapy in Canada. British Columbia introduced the treatment in 2010 and added it to the regular health care benefits (removing the requirement to “fail” treatment on methadone).17 The number of individuals on this treatment has subsequently increased.17 British Columbia is also experimenting with greater access to hydromorphone (dihydromorphinone) for patients with opioid addiction.7

Rapid Access to Addiction Medicine Clinics

Some jurisdictions run Rapid Access to Addictions Medicine (RAAM) clinics. These are low-barrier, walk-in clinics that can help guide a patient though substance abuse treatment and connect them with other services.20 They do not provide emergency services. RAAM clinics are available in Manitoba, Winnipeg, Thompson, Brandon, and Selkirk.21 In Toronto, there are RAAM clinics at the St. Joseph’s Health Centre, Women’s College Hospital, and St. Michael’s Hospital. These clinics serve patients requiring non-urgent care and increase access to OAT medications but do not manage acute withdrawal (especially in poly-substance use), so a large portion of withdrawal management still occurs in emergency departments (EDs).22

First Nations and Inuit Programs

In Sioux Lookout, Northwestern Ontario, there are 32 remote First Nations communities, with 22 of these communities having their own buprenorphine/naloxone programs. Initiation is performed by a community physician, who is present one week each month, or by urban-based physicians who fly in as a locum tenens (temporary doctors), with follow-up performed through telemedicine.23 As of 2017, these programs were treating 1,399 patients.23 Most programs are held in an unused or refurbished community building and have a service delivery team of program coordinators, medication dispensers, consultant counsellors, nurses, and physicians. The physician assists with the induction of buprenorphine-naloxone, and the community nurse or addictions worker dispenses the daily dosages. After induction, patients receive four weeks of intensive day treatment, with some programs providing an aftercare program consisting of trips of fishing, gardening, hunting, or traditional walks.23

Various pilot programs are also in use in remote First Nations communities. For example, in one Nishnawbe Aski Nation, a Suboxone low-dose program was piloted, with 30% remaining abstinent after six months. In Thunder Bay, the Dennis Franklin Cromarty High School piloted a drug program with clinical, cultural, and psychoeducational aspects for students.24

Despite relatively fewer opioid issues than other provinces and territories, Nunavut does have plans for three “healing camps” for addictions treatment providing “on the land” care that were proposed in August of 2018.25These are Cambridge Bay in Kitikmeot (Cambridge Bay Wellness Centre), Rankin Inlet in Kivalliq (Pulaarvik Kablu Friendship Centre), and the Qikiqtaaluk Region (formerly the Baffin region), location not decided.25 These camps would provide 28-day substance use recovery three to four times a year and potentially a 28-day outpatient treatment two times a year. Additionally, a Nunavut Recovery Centre with 32 beds to operate year-round was proposed.

Overdose Response and Supervised Injection Sites

Currently, British Columbia has an established Overdose Emergency Response Centre, with a strategic mandate of working to invest in and improve mental health and addiction services to combat the growing opioid crisis.26 One essential health sector intervention — “treatment and recovery” — is tasked with ensuring access to evidence-based medications and treatment, and ensuring the delivery of a continuum of treatments that combine both pharmacological and psychosocial aspects.

Many other provinces have naloxone kit or naloxone distribution services, such as Manitoba (started in 2017), the Northwest Territories,27 NL,28 and Ontario (Ontario Naloxone Program). 7 Nunavut has a focus on naloxone availability and education, as this jurisdiction does not have the same extent of opioid-related harms as other jurisdictions.7 In 2016, it was announced that the Government of NL will provide funding to the AIDS committee of NL (ACNL) and to the NL health authorities to create a harms reduction-based naloxone program.

Vancouver is home to the first safe injection site in the country (together with other harms reduction strategies),17 as well as low-threshold addiction treatment programs.7 As of 2018, Alberta runs four supervised consumption sites (with another five expected to open), with one providing supervised inhalation services.7 Quebec has four supervised injection sites, all located in Montreal.29 The AIDS committee of NL also runs the ACNL Safe Works Access Program (SWAP)30 — a needle distribution service in Corner Brook (with arrangements for delivery of supplies to outside of Corner Brook).

Hub-and-Spoke Models of Care

In Nova Scotia, the “hub-and-spoke” model is often used for MAT. In this model, a centralized “hub” is a specialized clinic that carries out induction and stabilization and manages complex cases. Nova Scotia currently manages approximately five such hubs.31 After stabilization, patients are then referred to primary care clinics — the “spokes” — to continue treatment. In this model, complex or difficult cases are managed by specialized providers, and allows for patients to transfer between the levels of care based on individual needs. Although the hub-and-spoke model allows for varying levels of specialized care, it requires strong communication between each level and, if demand for services increases past what the hub can provide, then a bottleneck effect may occur. 31

Yukon has a Referred Care Clinic in Whitehorse for providing opioid treatment. In 2018, Yukon released a 2018-2020 opioid action plan, which includes commitments to providing naloxone kits, increasing public awareness about opioids, surveillance of opioid-related deaths, and working on pain management across the province. Yukon is committed to consolidating opioid treatment to the Referred Care Clinic and building it as a hub of opioid treatment and expertise.32

Telehealth

Telehealth (also known as telemedicine) is the use of technology to provide health care services to patients.33 Telehealth can help lower barriers to care for patients with opioid addiction, as it facilitates connections between either providers and patients, or providers and other providers, for opioid treatment programs. This can eliminate obstacles to treatment such as distance to a facility or prescriber, strict surveillance of patients (requirements to come into the clinic daily), and assist with transitions between settings.33 Ontario has capitalized on the use of telehealth through the Ontario Telemedicine Network.12 In Stephenville and Springdale, NL, telehealth has helped doctors treat patients remotely instead of patients having to drive 250 kilometres to the clinic.34

Alberta also runs a program called the Virtual Opioid Dependency Program (originally Rural Opioid Dependency Program). This is provided through Alberta Health Services and is available for individuals living in areas without an established opioid dependency program. Appointments for initiation and maintenance of treatment are done via teleconference, with an individualized treatment plan. Medication is received at a pharmacy in the patients’ communities.35 Alberta also has an opioid dependency advice line for physicians to consult with specialists for advice on treatment.7

Correctional Setting

Canada

Federally, harms reduction strategies are available for prisoners, including OAT (methadone). However, needle exchange programs and clean needle provision are not common in prisons.36 A phased gradual pilot of two needle exchange programs (one at a men’s prison, one at a women’s prison) began in June of 2018 and is expected to expand in 2019.37 Appendix 4 details some non-pharmacological-based programs available for inmates in Canada. These include the Integrated Correctional Program Model and various national substance abuse programs. Access to OAT within the correctional setting is currently available in British Columbia. In that particular province, in both federal and provincial prisons, OAT can be either continued or initiated, using either methadone or buprenorphine/naloxone. In provincial settings, OAT was provided privately until September of 2017, when it was transferred to the publicly funded Provincial Health Services Authority.

In Alberta, within four hours of admission to a provincial correctional setting, an assessment is performed to determine which prisoners require additional addiction support and mental health services.33 Many facilities do not have policies that are specific to the management of withdrawal and addiction.33

There are 26 provincial adult prisons in Ontario. In a survey of physicians within these settings, there was representation from 15 of these prisons, with all participants stating that there was at least one physician who prescribed OAT. The majority of these participants indicated that they continued both buprenorphine (77% of physicians indicated that they prescribe buprenorphine) and methadone (100% of physicians indicated that they prescribe methadone) in their correctional setting if already prescribed it in their communities, with fewer participants initiating treatment in the correctional setting.

In NL, within Her Majesty’s Penitentiary (HMP) in St. John’s, MMT is supplied and a physician works with patients who were on MMT prior to incarceration.15 The health care unit at HMP includes a general practitioner, a nurse practitioner, an addictions coordinator, and staff nurses. They also have psychiatrists and psychologists available for the inmates.15 HMP houses all male inmates who were on MMT prior to incarceration, and these inmates attend mandatory weekly group sessions. Outside of St. John’s, the other four correctional centres have part-time contract nurse practitioners and monthly access to a psychiatrist. In the NL correctional centre, women have access to services from Stella’s Circle, and access its services continues in St. John’s post-release. HMP, West Coast Correctional Centre, and the Labrador Correctional Centre also offer the Integrated Correctional Program Model as previously detailed.15

Drug Treatment Courts

In Canada, federal drug treatment courts (DTCs) exist as a drug reform method, modelled after the US drug treatment court system. Since 2006, six DTCs have existed across Canada (located in Edmonton, Ottawa, Regina, Toronto, Vancouver, and Winnipeg).38 These DTCs provide intermediate supervision, substance use treatment, and behavioural treatments as an alternative to incarceration.39 DTCs are only available for offenders who meet specified criteria, including active addiction to “hard drugs” such as cocaine, crack cocaine, heroin (and other opiates), and methamphetamines.40 Appendix 5 contains a list of internationally recognized principles used in Canadian DTCs (Table 10) and a list of current DTCs in Canada (Table 9).38

Internationally

United States

In 2011, in the US, there were 1,103 programs that offered outpatient opioid services. Of these, 58.0% were for-profit businesses, 33.5% were non-profit organizations, and 8.5% were public programs. In 2002, the office-based administration of buprenorphine was approved by the FDA and, in 2012, 51% of opioid treatment programs (OTPs) offered it as a service.41 Federal law requires OTPs to provide medical, vocational, educational, counselling, and other assessment and treatment services, together with medication. OTPs must also be accredited and certified by Substance Abuse and Mental Health Services Administration (SAMHSA) or SAMHSA accrediting bodies.42,43 Providers are allowed to treat up to 100 patients with MAT (changed from 30 in 200643) if they hold a board certification in addiction medicine or addiction psychiatry by the American Board of Preventive Medicine or the American Board of Psychiatry and Neurology, and provide MAT in a qualified practice setting. 44 MAT in the US often follows a “high threshold, low tolerance” model, referring to a high number of structural barriers to service and a low tolerance for negative behaviours such as using or tardiness. These services often have forced tapering of OAT, high travel distances to programs, high financial costs to patients, a “not in my back yard” stigma, punishments for missed appointments, and high supervision and control over a patients’ daily life.43 Access to methadone programs is also restricted to patients who have had opioid addiction for more than one year.42,43

SAMHSA operates a buprenorphine practitioner locator45 and an OTP directory46 on its website. The OTP directory is sorted by state. OTPs were located in every US state (as well as the District of Columbia and the territories of Puerto Rico and the Virgin Islands) except North Dakota and Wyoming in 2015. As of 2019, North Dakota appears to have three available OTPs. Some states have specialized treatment centres in which methadone initiation, stabilization, and maintenance occur in one setting.31

Legislation for treatments for prescription opioid addiction vary state by state in the US, but they have state-run prescription drug-monitoring programs, extended naloxone access in law enforcement and paramedics, immunity from law enforcement for individuals seeking overdose treatment, expansion of screening and treatment for substance abuse, and prescription drug take-back programs.41

Vermont also runs a system similar to Nova Scotia, using a public health response to addiction through a hub-and-spoke model of care.47 However, some states are very strict with regulations surrounding OTPs and this limits the number available to patients (e.g., Mississippi, where only one OTP is available). This means that many patients will cross state borders to receive the care they need.47 Some states have various opioid-related projects occurring. In North Carolina, for example, the North Carolina Harm Reduction Coalition runs a grassroots advocacy initiative implementing harms reduction and public health interventions such as overdose prevention projects. There is also Project Lazarus — an overdose prevention program that provides training.48

Telehealth in the US is also used similarly to Canada. emocha, a mobile health technology company specializing in patient engagement and medication adherence,49 created an application to be used by patients in OAT, where they can film themselves on a smartphone camera taking medications that requires direct observation therapy and record doses and side effects. This allows clinicians to monitor patients’ adherence to medication, communicate with patients, and review progress.50 SAMHSA also has a smartphone app called MATx for health care practitioners providing care for opioid addiction.51

Australia

There are more than 46,000 patients using OAT in Australia.52 At public clinics in Australia, OAT is provided free of charge. In the community pharmacy, State Health Departments provide methadone free of charge and the patient pays a dispensing fee. General practitioners’ visits are covered under Medicare.53 Methadone is dispensed under direct supervision and after some time may be taken as two take-home doses per week.53 Australia has an opt-in OAT program in which 60% of pharmacies do not provide OAT.52 Approximately 43% of OAT is provided in community pharmacies.52 OAT is also delivered in Australia through specialized clinics, general practice, correctional settings, and through public hospitals, with abstinence-based therapies only supported by the government for alcohol dependence and not for opioid dependence.53 In New South Wales, there is a network of specialized OAT clinics within public hospitals, but in other parts of the country OAT is provided through community pharmacies. 53

New Zealand

OAT started in New Zealand in the early 1970s54 and buprenorphine was subsidized by Pharmac in 2012. In 2012, there were 5,018 patients in OAT. The Ministry of Health proposed an integrated model with general practitioner and specialist care at a ratio of 80% to 20% for New Zealand in 1992, but this ratio was eventually revised to 50/50. Currently, the percentage of patients continuing OAT in primary care is 29%. In 2014, New Zealand published practice guidelines for opioid substitution treatment. 55 These guidelines emphasized that treatment in New Zealand has a standardized method of person-, recovery-, family-, and whānau-centred care.55

European Countries

Opioids are the principal drug in 36% of drug treatment cases in Europe, and 628,000 individuals received OAT during 2016.56 The European Drug Report 2018 summarizes developments in drug-related treatment and prevention for 30 European countries and includes individualized Country Drug Reports for each country. These reports can be found on the European Monitoring Centre for Drugs and Drug Addiction website.57 In general, most drug treatment is provided on an outpatient basis and in specialized outpatient clinics, followed by “low-threshold” agencies. Drug treatment is also provided by primary care (including family physicians) and general mental health centres.56 In-patient services are provided in European countries in hospitals, therapeutic communities, and specialized residential treatment centres, but the extent of in-patient treatment varies between countries. 56

The primary intervention for opioid-specific drug treatment is OAT (provided in specialized outpatient settings, in-patient settings, and prisons), followed by psychosocial interventions such as counselling, therapies, and intervention support groups.58 In-patient treatment is not common but often includes prerequisites for entry, individually structured treatment, and psychosocial rehabilitation with the intent to reintegrate those addicted to opioids into society. National provision of OAT varies, with methadone being the most commonly prescribed OAT overall, followed by buprenorphine. In eight countries — Croatia, France, Sweden, Cyprus, Norway, Greece, the Czech Republic, and Finland — buprenorphine is more commonly prescribed than methadone. Buprenorphine is not prescribed in Ireland, Estonia, the Netherlands, or Romania.56

Similarly to Canada, European countries are also experimenting with e-health services and “m-health” (e-health provided through mobile phones) using virtual or digital technology to provide specialized care for individuals with opioid addiction.58 Examples of these programs include MijnJellinek — a Dutch program combining e-health and face-to-face therapy — and ORION (Overdose Risk InfOrmatioN tool), which calculates an overdose risk score for the patient, with the intention of starting a dialogue for health care providers and increasing awareness of overdose risk.58 According to a report by the European Monitoring Centre for Drugs and Drug Addiction, there are 67 smartphone-based apps for drug-related health services. These include apps that provide drug-related information and advice, apps that provide interventions for drug users, and apps that provide capacity building initiatives for health workers.50

United Kingdom

The drug treatment system in the UK is assigned to different local authorities in each country. These include local authorities in England, local health boards in Scotland, community safety partnerships in Wales, and drug and alcohol coordination teams in Northern Ireland.59

In the UK, services include community-based prescribing, one-on-one and group psychosocial interventions, in-patient treatments, partial and full-time residential treatment programs, and day programs. Outpatient, community-based, specialized drug treatment centres are the most common providers of drug treatments, including specialized OAT treatment centres. Methadone and buprenorphine (and infrequently, prescribed injectable methadone and diamorphine) are available from general practitioners and specialized doctors.59

France

France has a unique system in which buprenorphine is prescribed by general practitioners and dispensed by retail pharmacies,60 but methadone is only available in specialist centres.61 Buprenorphine is prescribed more frequently (59%) than methadone (41%).62 There are about 100 sub-regions of France, with the majority of these areas having a specialized drug treatment and prevention centre, the CSAPA. However, many opioid users are treated in hospitals as part of the general health care system, not in CSAPAs, and their information is not collected in the French data collection system.62

Spain

In Spain, the policies for drug treatment is overseen by the National Strategy on Addictions, but the autonomous communities are in charge of implementation and the provision of care.63 The Country Drug Report 2018 for Spain states that a specific drug dependence care network is distributed across the country, and care consists of both in-patient and outpatient services.63 OAT therapy has a coverage (a ratio of interventions provided to interventions needed) of approximately 60% (as of 2010).64 Currently, OAT is provided at 2,000 in-patient, outpatient, or other health centres.63 Physicians in private practice can be licensed to prescribe and dispense methadone at no cost to the patient.64 Buprenorphine/naloxone can be purchased by patients from all pharmacies, for a cost, but methadone must be collected from a dispensing centre.

In-patient services include: detoxification units, apartments for reintegration and treatment, and therapeutic communities. Outpatient services are generally low-threshold services working at a first-care level, screening patients and providing mental health treatment, or specialized drug treatment centres working at a secondary level. Specialized treatment centres are usually multidisciplinary and provide psychosocial treatments in addition to OAT.63

Greece

OAT in Greece is provided by the Organization against Drugs (OKANA), who manage “prevention centres, treatment units and social and professional reintegration centres.” 65,66 Other drug treatment programs are fully or partially funded by the government and include psychosocial interventions, outpatient treatment for both adults and adolescents, and specialized drug treatment centres.57 In-patient services are based on a 21-day detoxification treatment program in prisons, therapeutic communities, and residential drug treatment centres.57 As of 2016, 66.4% clients were entering specialized treatment centres for opioid use.

Other organizations provide support and treatment for addictions, including the Therapy Center for Dependent Individuals (KETHEA). These organizational programs are established in various areas of Greece and are generally abstinence-based, counselling-based treatment centres or programs. 67

Ireland

Harms reduction in Ireland has broad support through drug policies and practices. Needle and syringe programs are provided in 24 permanent sites, 14 outreach sites, and in 129 community-based pharmacies.65 OAT has been available since 1992, and is provided by treatment centres, general practitioners, and within the correctional setting.

Italy

In Italy, the drug treatment focus is more commonly on prevention and abstinence, or reduction of drug use, and not on harms reduction strategies. Despite this, OAT — both methadone and buprenorphine — services are available in the community, most commonly in the northern and central urbanized regions of Italy.65,68 These services include fixed sites, mobile dispensing units, outreach, and needle disposal and dispensing services.65 Drug treatment is split into two subsystems — the public drug dependency service units providing outpatient services and the social-rehabilitative facilities providing mostly in-patient and semi-outpatient services. Interventions available include psychosocial supports, psychotherapy, detoxification, and vocational training.68 OAT is available through general practitioners and specialized treatment centres, but it is most commonly initiated in public drug dependency service units.68

Sweden

Health care and social services have joint responsibility for addiction services in Sweden.69 In Sweden, the general view of opioid treatment is that it should be used as social rehabilitation and "normalization" — i.e., getting patients back to a "normal" life and integrating them into mainstream society.69 The national regulations are issued by Socialstyrelsen (the National Board of Health and Welfare), and these tend to be fairly restrictive relative to other countries.69 Opioid programs can only give OAT to individuals over the age of 20 who have been opioid-dependent for at least one year. To be eligible, dependence must be on heroin, morphine, or opium and not methadone, buprenorphine, or fentanyl, and no poly-substance use is tolerated. Medication is administered with daily supervision for at least six months.69

Literature findings and survey results from research question 3 are addressed in this objective.

Survey Results

Wait times for opioid treatment can vary substantially and standard or recommended wait times for opioid addiction are dependent on the location and the type of and demand for a service or program. Wait times can be heavily influenced by the prevalence of opioid use in the region, the style of service model implemented, and staff vacancies.70 Eight respondents stated the standard wait time policy was 0 to 2 weeks of waiting time, and actual wait times appeared to not deviate substantially from the standards or policies in effect for each program. In some regions of Northern Ontario, standard wait times were reported to vary from one to three months in outpatient settings, to three to six months for in-patient and post-treatment. However, in the Opioid Maintenance Therapy Initiative in the Northwest Territories, standard and actual wait times were reported to be zero to two weeks for treatment. New Brunswick (Elsipogtog Health & Wellness Centre) also had longer-than-average wait times of one to three months.

Some programs run a cancellation wait-list policy within their system. This wait-list approach is similar to a regular chronological wait list, but upon each intake cycle more patients than the number of available beds are processed and prepared. The additional patients are available to take the place of individuals who may cancel, be incarcerated, or not show up for treatment. If the prepared patients do not take a cancellation, they are guaranteed to be accepted into the next cycle of patients. This is to ensure that the program is at maximum capacity and that beds are always full.

Appendix 7 details the standard and actual wait times experienced by various programs in Canada, as provided by survey results. Table 2 details strategies and initiatives used in facilities to improve wait times for clients. Initiatives included allowing walk-ins, providing wait time data, adding more staff, integrating care, and using alternative health options, such as Telehealth.

Table 2 : Strategies to Improve Timely Access to Opioid Treatment — Survey Results

What strategies or initiatives are in place at your facility/setting to improve wait times for patients entering opioid addiction treatment?
Walk-Ins and Fast-Tracking Allowing walk-in intakes; providing a cancellation wait-list process and "sit and waits" (replacing "no-shows"); next walk-ins coming straight from EDs
Extremely high-risk patients fast-tracked (e.g., pregnancy, injection users)
Rapid access walk-in models of care; streamlining intake and assessment processes
Updating and Providing Wait-Time Data Regularly updating wait lists; regular wait-list and wait time reporting
Using electronic wait lists for program areas; providing real-time data
Specific Local Strategies With high-concern areas, following up and creating specific and local strategies
Making local areas accountable for their wait lists
Adding Staff and Prescribers Getting more individuals able to prescribe (including adding nurses who can prescribe); higher caseload capacities; additional staffing; having nurses provide intake and assessments; adding OAT case managers for patients outside of urban area; adding a dedicated NP to streamline processes
More physician education
Using private clinics in addition to staff at program
Pursuing Alternative Care Options Pursuing telehealth
Transportation initiatives to improve access
Having Integrated or Seamless Treatment Integrated treatment for mental health and addiction problems
Seamless care between EDs and other services
Other Strong support from the Chief Medical Officer

ED = emergency department; NP = nurse practitioner; OAT = opioid agonist therapy.

Literature Results

Ideally, patients requiring opioid addictions treatment would be accepted into treatment immediately. However, general barriers exist in all jurisdictions in Canada. Patients are more likely to attend initial appointments when randomized to a rapid access treatment (seen within one to three days) versus a regular clinic (seen within two to four weeks). In one study, delay in treatment was a strong predictor of treatment drop out, stronger than individual patient characteristics or readiness to change.22

Health Quality Ontario published quality statements for improving the quality of care for patients with opioid use disorder (in all settings). These quality statements recommended that individuals diagnosed with opioid addiction should have access to OAT within a maximum of 3 days. They also state that treatment of moderate to severe withdrawal with buprenorphine/naloxone should occur within 2 hours.71,72

Health Quality Ontario reported wait times for general addiction programming in Ontario, in 2012-2013, as 42 days for residential treatment programs, 16 days for community treatment programs, and nine days for community day or evening programs. This was reported to be an improvement of seven, 10, and three days, respectively, over the 2008-2009 reports.73 In the Toronto Central Local Health Integration Network (LHIN), wait times were a week, 25 days, and up to 17 to 34 weeks for community day or evening treatment, residential supportive housing, and residential treatment, respectively.2222 In Winnipeg, Manitoba, the Opioid Assessment Clinic at the Health Sciences Centre had a waiting time for assessment of approximately three months, and the Addictions Foundation Manitoba methadone intervention & needle exchange (m.i.n.e.) program had a wait time ranging from a couple of days to a year.21,74 In Alberta, times to access adult outpatient addiction services for 90% of patients ranged from 0 days in the Calgary and Edmonton Zone to 21 days and 24 days in the South Zone and in the North Zone, respectively (both of these zones are rural areas). These are compared to the provincial 2017-2018 targets of 12 days.70 In one study,75 incarcerated patients continuing OAT in Vancouver, British Columbia waited a median number of two days to receive their first dose, and incarcerated patients initiating OAT waited a median number of two to three days.

The Canadian Mental Health Association reported wait times for addiction treatment as ranging from two weeks to one year, with public services having longer wait lists than private. In 2013, 65% of 203 surveyed public programs maintained a wait list, and 56% of these were "overburdened" with this waiting time.76

Objective 3: Factors influencing wait times for opioid addiction treatment programs in Canada

Literature findings and survey results from research question 4 addressed this objective.

Survey Results

Barriers

Themes that emerged from the survey included transportation and rural and remote locations, no-shows and scheduling difficulties, staffing and spacing, funding and demand of services, lack of training, lack of integration of care, and stigma. These themes are summarized in Appendix 8 , Table 12 .

In many areas, there is limited public transit or no infrastructure for supporting travel. In remote and rural locations, it can be worse —there may be long travel distances to and from pharmacies and treatment. Canada is a large country, with many rural and remote communities that may not receive the care they need. With methadone treatment often requiring daily attendance at a pharmacy, this is a major barrier for patients who wish to start OAT. This, combined with treatment only being available in specific places (e.g., urban centres), creates an inequity of access and a barrier to the timely access of treatment.

Treatment can be delayed by both client issues (including no-shows or missed appointments, a recent use of opioids, or schedule issues), and facility issues (including limited opening hours or no options for weekend appointments). Running an opioid program also requires space — the demand for opioid treatment has increased and is constant. This overwhelming need for opioid services creates programs that are often at capacity because of limited space and support, which limits access for new clients. Insufficient staffing was another major barrier for timely access — limited nursing staff, prescribers, physicians, and pharmacies and pharmacists to dispense medication were cited as reasons for not meeting recommended wait times. Together with limited staff, it was noted that limited training of staff also creates barriers for timely access to opioid treatment, and limited funding and remuneration also creates barriers.

It was noted that often clinics work in silos and are often not connected well to one another. This lack of integration of services was mentioned as a barrier to timely access — specifically, a lack of providers in the community to discharge patients to from the correctional setting was cited as a major barrier. This barrier is also discussed in Objective 5 for continuity of care.

Facilitators

Themes that emerged from the survey as facilitators to timely access of opioid treatment included staffing and appointment times, collaboration, alternative care options and technology, support from government, guidelines and education, and having integrated or seamless treatment. These themes are summarized in Appendix 8 , Table 13 .

While staffing and appointment times can be a barrier to timely access, it was also mentioned as a facilitator to access, as well. Some respondents noted that their programs had flexible appointment times and multiple bookings per day, as well as staff members who went above and beyond the call of duty to assist with the program. These "champions" dedicate time outside clinic hours and were noted as being particularly skilled at providing care for patients. It was also noted that having nurse practitioners be allowed to prescribe OAT was particularly helpful, as they could dedicate a nurse practitioner to do this task.

Another factor that also serves as a facilitator for service was having integrated treatment services for patients. Respondents mentioned that streamlined paperwork and triaging for patients, as well as having specific case management at the territorial level , helped with care. One respondent mentioned having developed functional, seamless care pathways between services and EDs, detox and withdrawal management settings, OAT clinics, and primary care. Similarly, collaboration between services was also noted as a facilitator — including collaborations between the EDs and the community; collaboration with the Royal College of Physicians and Surgeons of Canada , the Newfoundland and Labrador Pharmacy Board , and the Association of Registered Nurses (of Newfoundland and Labrador); and collaboration with and access to private clinics.

Additional facilitators to timely care were alternative care options and the use of new technologies to assist in patient care, including telehealth and electronic medical records

Literature Results

There are numerous barriers to care that a patient with addiction may face, which impact the timeliness of treatment. These barriers are well-established in the literature. An overview of common general barriers is outlined in Table 3.

Table 3: General Barriers to Timely Access to Addiction Services

Barriers to Opioid Treatment
Resource Barriers
Lack of remuneration OAT clients are often more time-consuming than other types of patients and may be a more challenging patient group. Fee-for-service physicians may not want to risk no-show appointments, as they result in a loss of money for the physician, so they do not open clinics .31Salaried physicians in collaborative teams may be more likely to provide OAT and benefit from the support and access to resources, but fee-for service physicians and physicians early in their career may be more cautious to offer OAT (especially when new to medicine and trying to establish their own practices).31
Limited number of providers and training Many areas do not have enough prescribers of OAT. The ability to prescribe methadone is quite limited and requires a special exemption (as of 2018, no longer required13).77 Some physicians do not feel they have enough knowledge or training to provide these services.17,31 Primary care physicians are often not taught about substance use disorders in medical school.31
Private services are too expensive for some patients If a patient decides to use private services, these can be quite expensive. Many patients cannot afford this type of treatment. Patient-paid programs range in Alberta from approximately C$20 to C$200 per day, most commonly at C$40 per day.78
Client is a youth or adolescent Services that can cater to clients who are adolescents are limited. A younger age is associated with less likelihood of receiving treatment or pharmacotherapy for addiction.79 Some programs have strict minimum ages.
Services are strict in entry criteria Some services are strict in entry criteria (e.g., no poly-substance use), which limits the available services for people with poly-substance addiction. Many programs require a certain number of days of drug abstinence before admittance.78
System Barriers
Transportation not available or clinic too far away Some patients must travel hours to receive dosages of OAT.12 In remote, rural, and northern regions, this can be very difficult. Take-home doses can require daily travel to the clinic for about eight months, but the federal Non-Insured Health Benefits funding only subsidizes four months of travel to the clinic.12 Some patients do not have access to transport.31 Some clinics are highly isolated from other clinics (therefore, physicians are isolated from one another and are unable to provide support or advice). This isolation also makes it difficult for specialized methadone clinics to assist with patient care if they are not located nearby.31 There is geographic variability in provider number — it can range from zero providers per 1,000 patients in rural areas to 20 per 1,000 in urban areas.17
Addiction services do not exist Addiction services may simply not exist for patients in their communities or areas.80
Unaware of services If they do exist, patients may simply be unaware that services exist for them or unaware of how they work.80
Wait times are too long for provincial services Subsidized and provincial services often have very long waiting lists for clients because of volume, staffing, and other factors.76 Long waiting lists may deter patients from starting treatment.54
Services are often not provided in a language other than English or French It is important to provide services that can be understood by the client. If a client is not fluent in English or French, it may be difficult for them to understand the services provided and so they may not seek treatment.80
Altitudinal/Rational-Emotive Barriers
Concerns about diversion Patients may not receive OAT if providers are concerned about diversion of the medication.77,81
Physicians are reluctant to provide OAT, or worried about their careers Some physicians do not want to incorporate OAT in their practices.31 It has been reported that some physicians may be worried about the clientele they will attract, stigma around their practices, or bring the attention of governing bodies to their practices.31 Physicians also dislike the "supervision" aspect of providing OAT, feeling as though they are surveilling the patients too closely and therefore cannot build a rapport or a trusting relationship with them.31
Public opposition and zoning laws The public may consider harms reduction strategies to be an endorsement of drug use and oppose their use.82 Many municipalities enact zoning restrictionsa and bylaws that limit the access to OAT clinics by restricting where these clinics can be located or distributed through making "methadone clinics" and "methadone dispensaries" a distinct category from health care or social services.83 These restrictions on the use of land for purposes of harms reduction and treatment are often related to the concept of NIMBY-ism, where communities organize to oppose certain developments in their neighbourhoods.83 As health care in Canada is a provincial responsibility, municipalities cannot technically create legislation that affects access to health care services, such as services for methadone addiction. Although methadone addiction services is a provincially funded form of health care in British Columbia, be cause of the stigma surrounding drug users and their behaviour, residents of municipalities often want to "put" drug users elsewhere.83 Five Ontario cities (London, Windsor, Quinte West, Belleville, and Woodstock) have introduced bylaws that restrict OAT clinics and separate them from other medical services. Some cities may also look at the opening of methadone clinics on a case-by-case basis, with no predefined requirements for opening them, limiting timely access to treatment for patients who may not have a local clinic to attend.81

BC = British Columbia; NIMBY = not in my back yard; OAT = opioid agonist therapy.
"Zoning is when municipalities regulate land through bylaws and control the use of the land space for the health, safety, and general welfare of their residents.83

Correctional Setting

While the correctional setting often has barriers similar to those in the community, there are also barriers unique to this setting. In a survey of 27 physicians working in correctional facilities in Ontario, the most common barrier to prescribing OATs was concerns about the diversion of medication.77 There were also concerns about initiating treatment for prisoners who were not currently using opioids and whether this was appropriate, and there were concerns about a lack of access to community-based providers upon release and concerns about adherence.77 Lack of support — whether nursing support, institutional support, or patients not being brought to the attention of the physician — were also barriers to the implementation of OAT.77 Thirteen physicians did not prescribe methadone, with nine of these physicians stating they did not have an exemption to prescribe methadone and therefore were unable to prescribe OAT. It was stated that OAT is under-resourced and is a large burden on health care staff in the correctional setting, with one participant stating that the initiation of OAT should be only done when the ministry provides appropriate resources to facilitate it.

More than 30% of participants in the survey agreed that supports — in the form of support from health care staff and administration in the institution, additional resources for program delivery, and access to linkage with the community — would facilitate the use of OAT in the correctional setting. It was also noted by two participants that better remuneration would be a facilitator to OAT-prescribing, as the time requirement and liability potential of this opioid addiction population is quite high. This barrier was also mentioned within our survey that follows in the next section.

Physician Barriers

Some physicians question the effectiveness of OAT for prisoners in the correctional setting, believing that initiating OAT in prison is inappropriate regardless of ministry policies, and that it is not an effective treatment for opioid addiction in this environment. 77 It was mentioned by some physicians that, in this context, they believed OAT is not more effective than counselling and referral to treatment post-release. It was noted that there was a lack of optimism about the treatment for this population, especially in repeat offenders. They were unsure how the treatment was helping the population when a number of inmates continue to use regardless of treatment.77

Many physicians appeared disillusioned with the initiation of OAT in custody, stating that they have initiated the medication previously and had the patient divert the medication, and were concerned about OAT becoming "currency" for inmates (and the safety issues and overdose potential this has).77 Formulations of Suboxone in sublingual tabs also makes diversion much easier. There were also complaints of inmates with factitious complaints asking for medications such as benzodiazepines and the concern that the concurrent use of methadone or Suboxone with these other medications will increase overdose potential.77

Objective 4: Patient characteristics or prioritization criteria in use for determining entry to opioid addiction treatment programs in Canada

Literature findings and survey results from research question 5 addressed this objective.

Survey Results

The majority of respondents (79%) answered questions regarding criteria for entry into their programs and the prioritization criteria used to select patients. Appendix 9, Table 14 outlines survey responses to these questions. Many programs, at minimum, required a diagnosis or needed-to-meet criteria for a substance abuse disorder (as defined in the DSM-V) prior to acceptance into treatment. Some programs did not require any criteria for entry (outside of assumed "problematic opioid use"). One program required the provision of a urine sample prior to treatment.

Most programs did not have prioritization in their treatments, as they accommodated all patients, but a few programs prioritized persons who are pregnant, use injectable opioids, had a recent overdose, are adolescents, or who live with HIV.

Literature Results

The College of Physicians and Surgeons of Nova Scotia released a Methadone Maintenance Handbook14 that recommended that physicians consider patients for methadone therapies after a thorough assessment and discussion about treatment. Within the assessment, the physician should consider four factors:

  • an opioid use problem; this can be confirmed with a urine drug screening that is positive for opioids
  • meeting the DSM-V criteria for opioid substance use disorder
  • no contraindication to methadone
  • patient agreement to the terms and conditions of the program.

In the US, SAMHSA released federal guidelines for the provision of OTPs.42 The patient characteristics to determine entry into OTPs includes a determination, using accepted criteria such as the DSM-V, that a patient is addicted to an opioid drug, has been addicted for more than a year, and is voluntarily choosing treatment. Some criteria can be waived under certain exemptions (e.g., pregnant patients can waive the year requirement).42

Objective 5: Current practice as it relates to supporting patients receiving opioid agonist therapy through care setting transitions

Literature findings and survey results from research question 6 addressed this objective.

Survey Results

Respondents were asked questions relating to barriers and challenges for patients transitioning between settings, and approaches and support used to assist patients with transitions. Respondents were also asked about barriers to assisting in the identification of potential challenges to the implementation of transitional policies or guidelines. Appendix 10 , Table 15 , Table 16 , and Table 17 , detail the survey answers given, organized into main themes and setting transitions.

Barriers and Challenges

Overall, respondents noted that barriers within transitional settings were similar to some barriers experienced with receiving timely opioid treatment — including stigma, a lack of knowledge from providers, a small number of available physicians, difficulties in access, and difficulties in transportation. It was noted that, overall, transitions can be difficult, as many doctors and emergency departments do not want to prescribe or start OAT therapies for patients despite the ED being one of the main contact points for patients initiating treatment.22 EDs may also want specialist clinics to initiate OAT, but specialist clinics are unable to do so when the patient is in care of the ED. Conversely, after some ED physicians initiate OAT, some community physicians do not want to maintain patients on OAT when transitioning from the hospital setting, either from a lack of desire to prescribe OAT or from a lack of the same hospital privileges that allow them to prescribe the medication. This leads to patients leaving the ED either without a prescription entirely, or with a prescription and no way of continuing treatment or renewing the prescription after release. These breaks in medications can be detrimental to the patient, as it allows for withdrawal symptoms to appear and may prevent long-term harms reduction.

A lack of communication was noted by many respondents; communication is challenging when moving both internally and externally, and a lack of general opioid addiction oversight in primary care with no provincial policies results in recommendations which are not consistently met for transitions of care. It was mentioned that patients may be admitted to in-patient settings and discharged without having a consultation with an agonist prescriber, and this lack of communication results in the patient not receiving adequate care upon transition from the in-patient setting. In was also mentioned that electronic medical records are not always integrated, which means there is inadequate or incomplete information shared among providers. This was also mentioned in the literature as a major barrier in transitioning — clients transitioning from private to public services with no records being shared.75 The number of doctors who fill in temporarily  in some EDs can prevent transitions to primary care that can provide OAT, and the doctors on duty are unaware of who provides these services when withdrawal starts to occur. Communication was also noted as an issue in the Yukon correctional setting: prisoners can be put on remand, attend court, and be released in one day, without the clinical side of corrections being notified. Nor is the prisoner put in contact with them, so the prisoner does not get an opportunity to initiate OAT or be directed to somewhere they can. Additionally, it was mentioned that some correctional facilities will release most prisoners on a Friday, with the addictions centres not open on weekends to take them to continue addictions supports. This issue was also present in the literature, especially for clients in pre-trial settings who may be released after court without notice, so a physician cannot assess a client and prescribe OAT.75 This fragmentation of care in correctional settings upon discharge is a major barrier to care for prisoners.75

Along with a lack of communication, respondents noted a lack of pharmacies and clinics in general that contribute to difficulties in transitions between settings. This includes in the injectable OAT setting to correctional settings, correctional to community settings, and from contact with the health care system to detox settings. A lack of following guidelines in some private clinics were mentioned, with some "boutique" clinics not fully catering to the primary needs of patients and stricter rules about poly-substance use potentially leading to fragmented care for the client.

Supports, Practices, and Approaches

Communication was noted again as a theme in practices and approaches used to ensure the continuity of care. Some programs are integrated in a continuum, some programs have ongoing fax and phone calls or telephone consults between programs, and some have forms that are filled in prior to transfer. However, some programs do not have transfer plans in place, at least not formally. Supports for patients in transitory settings include the implementation of specific case managers who facilitate and coordinate care between the OAT prescribers and the community pharmacies, telephone work with team leads that coordinate care, case management from the ED to primary care, and outreach registered nurses, or RNs, who assist with transitions. There are also outreach staff in OAT clinics who meet with patients, transport them, provide information, and connect patients in one facility and assist in their transfer to the OAT clinics. One respondent said that, in their opinion, the outreach service has been the most beneficial service to assist with transitions out of all other initiatives.

In settings that have a high percentage of First Nations patients, having culturally competent services is critical to the success of providing for this population, as First Nations peoples are more likely to respond to care from someone who they identify with. It was noted that transitions are more manageable in services that are culturally sensitive, and that transitions can be frustrating for both the patient and the organizations when agencies do not match in philosophies of service delivery.

Some programs use step-up, step-down care to assist in transitions between programs. This is the option for patients to transition between levels of intensity of services (e.g., moving from residential to outpatient care if struggling with the former). Step-up, step-down care is available for programs that have integrated care but not available for stand-alone programs. Other programs use warm transfers, or warm hand-offs for clients transitioning to other programs, including from EDs and from the correctional centres. Patients are referred before leaving the centre and intake for a community clinic is done immediately. Other programs also use electronic medical records to increase communication between OAT clients; this helps make acute care aware of proper dosing and provides a continuity of information across the health care system. Finally, some programs use specific staff to help facilitate transfers, including mental health nurses, ED doctors, and addiction counsellors.

The Dilico Anishinabek Family Care centre also provides housing support within the continuum to assist patients. This includes assisting patients to transition to a supportive transitional living environment and rental support with case management associated with it. This housing support is realized under the Local Health System Integration Act.

Literature Search

Appropriate transition between settings is a key to maintaining continuity of treatment and not allowing patients to slip through the cracks. In an ideal situation, all patients would receive appropriate, timely care, with no gaps in treatment and with appropriate transitions between programs. However, some gaps in treatment can occur because of the belief that addiction is solely a psychosocial issue and is therefore not part of the greater health care system.22 Continuing to create a separation between addiction programming and "regular" health care systems can cause patients to not receive addiction medications in EDs, primary clinics, or hospitals. This belief also can create a lack of access and a lack of opportunity for patients to be referred to the appropriate treatment after undergoing withdrawal management or discussing their addictions with their primary care providers.22 Patients seeking withdrawal, depression, overdose, or infection help in EDs will also often leave EDs prior to being seen by the physician if their withdrawal symptoms (which can occur rapidly after the previous use of opioids) become too distressing and they are not promptly seen. This does not allow the patient access to long-term care on an appropriate OAT medication or access to referrals to other treatment centres.22 To overcome the barrier of treatment fragmentation, multidisciplinary and collaborative approaches have been proposed, such as the rapid reintegration of buprenorphine/naloxone in the ED with a coordinated referral process to primary care.17

In Ontario, RAAM clinics appear to help support patients transitioning through the opioid treatment system. A patient who presents to the ED with withdrawal symptoms, either from alcohol or opioids, receives withdrawal management and is referred to an addiction-specific physician at a RAAM clinic.22 This pathway attempts to ensure the continuity of care. An alternative pathway is through the community — community providers (e.g., detox centres, shelters) can refer patients to the RAAM clinic, where they are seen within seven days.22 Rapid access clinics can result in fewer ED visits, reduced wait times, and higher treatment retention.7 Ontario also published the Methadone Treatment and Services Advisory Committee, Final Report in 2016 that recommended and committed to providing funding for RAAM clinics and to creating a more integrated care pathway for treatment.84 Assertive Community Treatment teams connect patients to resources, case management, and outreach services, and are also available in Ontario.7

In this care pathway, the addiction-specific physician prescribes OAT, refers and connects the patient to other treatment programs, and a therapist provides counselling. After stabilization, long-term care is passed to the patient"s primary physician, with full transfer of care to the primary care provider . In the early stages of treatment, however, RAAM clinics can help to deter a relapse by referring patients to immediately available resources, such as Narcotics Anonymous and Withdrawal Management Services (WMS).22

The Canadian Centre on Substance Use and Addiction published a 2018 report, Best Practices across the Continuum of Care for the Treatment of Opioid Use Disorder.7 Overarching principles for best practice included:

  • The patient determines the ultimate goal of treatment.
  • The treatment plan is made in collaboration with the patient.
  • Treatment includes all components of well-being, including physical, mental, and social well-being.
  • Treatment should be culturally competent.
  • Stigma should be reduced.
  • Treatment should be peer-engaged.
  • Recovery-oriented systems of care are recommended.
Warm Transfers, or Warm Hand-Offs

Warm transfers or warm hand-offs are a method of transition care that attempts to introduce a patient to and between care programs gradually, as opposed to abruptly handing them off to another service with no guidance. This can include directly introducing a patient to another care provider, which helps to engage the patient in their care and prevents communication breakdowns.85 This style of transfer is also designed to minimize no-shows at services, especially between overdose management in an ED and withdrawal care and OAT care in the community. ED transitions are one of the most vulnerable times for patients, as this is when they are often very motivated to seek treatment but may lose this motivation once discharged and not promptly seen. Currently in the US, Illinois has 12 hospitals using this system, mostly in Chicago. In these hospitals, a support worker comes directly into the hospital and encourages patients presenting with addiction issues to enter treatment prior to leaving the hospital.86 Pennsylvania also has a warm hand-off program in which a patient presenting to the ED with concern for opioid use disorder would be warmly handed off to a drug and alcohol assessor prior to discharge, or warmly handed off to in-patient services if not safe for discharge.87

Warm hand-offs were also mentioned in the abovementioned survey results. This was in the context of the Yukon Department of Justice, where a client is introduced to a community care provider before leaving the correctional facility, but this warm transfer also occurs in the community care clinics. The goal of this transfer is to provide education on how the community OAT program works and to build some rapport with the patient to encourage them to stay in, or to seek treatment. Warm transfers were also noted to be used in AFM, as much as possible.

Evolving the System — Toronto Central LHIN22

In 2015, the Toronto Central LHIN prepared a report with recommendations regarding addictions treatment, including opioids and alcohol, using a community-based engagement process (focus groups, interviews, a planning summit, and working groups).22

The report recommended that services should become more coordinated because there is a lack of standardization and centralized assessment and referral for addiction services. The authors also noted the lack of integration of services and fragmentation of knowledge around available services, and a lack of communication between organizations, especially those with different philosophies on treatment. The overarching recommendations to "evolve the system, seamless flow, flexible options, and access to all clients"22 included standardized intake so that a "no wrong door" philosophy is met (i.e., everyone, regardless of situation, experiences the same flow through the client pathway), reformed emergency services that require hospitals to have an addiction strategy that allows appropriate triaging and connection to services, and to improve time-to-access and flow through WMS and referral to treatment. Improvement of access time and flow included the creation of a working group within intensive treatment services to facilitate prioritization of specific client groups, a reduction of wait times, and appropriate case management. A high-level client pathway was developed to visualize care through addiction services, detailed in Appendix 11 . The model of care was designed so that clients entering the addiction care service would receive support that is standardized and meets their individual requirements.

High-level themes from the focus group and community consultations conducted by the Toronto Central LHIN included principles that ran "across" the system — e.g., services should be coordinated and seamless, services should be integrated (a coordinated addressing of physical and mental health needs), there should be access between services or programs with differing treatment goals and transitions should be fluid, and there is a need to better share information between programs (such as via electronic medical records). Within the system, it was noted that care is fragmented between the community and medically based withdrawal, and there needs to be more medical and clinical support to address this.

Recommended in this pathway is the creation of a standardized intake and matching processes. Currently, patients may connect with the services through a variety of ways, but individual providers may not be aware of places to refer patients or have relationships with other providers. Without connections to other providers, patients may not receive the appropriate care, and there may be overcrowding in one part of the system even if there is capacity to assist in another.

Currently, the ED is a common place for individuals to have first contact with the health care and addictions system. Often after stabilization, patients are referred to a central access line, but more than one-third of patients then return to the ED within 30 days. It is suggested that the ED is a critical point that can facilitate transitions to treatment and improve patient outcomes. The working group proposed an ED flow that sees the patient referred from the ED to a rapid access clinic or an addictions consult team, who then provide short-term case management and peer support, and then refers the patient to WMS and supported stabilization services. These transitions would also use warm transfers, or warm hand-offs.

One recommendation from the focus groups and community engagement process for the Toronto Central LHIN was to improve the time and flow from referral to treatment, to combat the gap in time between a referral to intensive treatment and the actual receipt of the treatment. Gaps in time between withdrawal and treatment may result in patients who go through many rounds of withdrawal, which may cause patients to become disillusioned with treatment. Improving flow can occur through a few factors, including using intensive treatment to its full capacity, increasing agent accountability for their capacity (i.e., providers should pull patients to treatment when they have capacity), and to prioritize patients for treatment who are coming from WMS. When wait times are unavoidable, short-term case management should be used including psychosocial support. This recommendation is similar to SAMHSA's recommendation of the provision of interim care in lieu of solely a wait list.88

Transitions From Correctional Settings

Release from prison to the community is one of the most vulnerable transitions in the care pathway. Prisoners released from correctional settings who do not seek help or have access to services (either mental health or substance abuse) are likely to reoffend.88 In one study,77 Ontario physicians were asked about the delivery of OAT in provincial correctional settings. Participants in the survey noted challenges to the continuity of care both in custody and upon release. One participant noted that the majority of the population they treat are in transient custody and may see multiple physicians day to day, as physician coverage may change daily and prisoners may change units frequently. The surveyed physicians mentioned that, because a lot of prisoners are on remand, they are often not ready to have a discussion about MMT with them, as the patient may not appear for another court appearance. Participants also mentioned the challenges of ensuring community care upon release, as it is difficult to find a community care provider that would follow up with a patient and also ensure that the patient follows up.77 With many prisoners having a lack of primary care available to them, no permanent address upon release (often a prerequisite for methadone clinics), and no health card, it can be difficult to guarantee community care. One of these survey participants noted that they had specifically developed relationships with community providers in order to support the continuity of care upon release. They noted that community providers are aware of individuals who start methadone in the correctional setting, and that they agree to take patients directly into their programs upon release, with no gap between treatments.77 This study therefore recommended establishing linkages with community-based care to ensure the continuity of treatment. 77 However, it was noted that if patients fail to follow up with community providers and are re-arrested, they may not be able to start methadone management in prison again.77

In 2018, SAMHSA published Guidelines for Successful Transition of People with Mental or Substance Use Disorders from Jail and Prison: Implementation Guide.88 This guideline is for general behavioural issues but extends to opioid addictions as a component of substance abuse disorders.

These guidelines use an acronym — APIC — which stands for "assess," "plan," "identify," and "coordinate." With this acronym, there are ten guidelines to help plan transitions for prisoners leaving the criminal justice system.88 These guidelines include:

  • universal screening upon entry to the facility, as early as the intake process, to detect substance use or behavioural issues
  • if positive for substance use, perform a comprehensive assessment of the prisoner to guide program placement and decide on which services to provide; this assessment includes demographics, clinical need, what supports the prisoner has (family and community), and public safety or risk
  • develop an individualized treatment plan
  • develop a collaborative approach between behavioural health treatment and the criminal justice system
  • anticipate the vulnerable period post-release; identify appropriate interventions as part of the transition-planning process
  • develop policies that facilitate the continuity of care through direct linkages (e.g., Warm Transfers, or Warm Hand-Offs)
  • support adherence to treatment through a coordinated approach; provide incentives and gradual sanctions to the prisoner as rewards to encourage compliance, with standard protocols that deal with violations of conditions of release
  • develop mechanisms that support the sharing of information across programs at different places in the criminal justice system
  • encourage cross-training between organizations
  • evaluate program performance and identify gaps in treatment.88

For recommendation number six — facilitating continuity of care — one option includes appointing specialists (e.g., pre-release coordinators or specialized re-entry probation or parole officers) who work with inmates in preparing them for release, including planning for physical health care, behavioural health care, and community supports. This could be as involved as just connecting the inmate with these supports and leaving them to follow up, or as involved as personally transporting the inmate and introducing them to the supports.88

One study from the US89 described implementation strategies and a project (MAT Implementation in Community Correctional Environments, or MATICCE) to improve inter-organizational relationships between the correctional setting and the community providers. One project attempting to reduce system-level fragmentation of services for homeless individuals with serious mental health issues (Access to Community Care and Effective Services and Supports) had planned strategies including building interagency coalitions and interagency teams for service delivery, cross-training staff, and developing more formal interagency agreements. The project resulted in more integration between services but not always better client outcomes.

MATICCE focused on structured communication between parole agencies and community treatment agencies using a "local change team." This local change team had eight to ten staff from the community agency and the parole agency, as well as other OAT treatment agencies. Firstly, the change team identified current policies and procedures that either prevent or facilitate the referral process of OAT clients, then developed a strategic plan with objectives from three domains: building relationships, getting buy-in from staff, and financing OAT. It then implemented the strategic plan.89

Strengths of the MATICCE process were noted, including how it often involved front-line staff in planning, as well as improved engagement. But other barriers were also noted, including how corrections officers and community treatment staff often have differing organizational cultures, and that many organizations are reluctant to share information among one another about clients for fear of confidentiality breaches and the US Health Insurance Portability and Accountability Act.89

Other strategies mentioned included setting mutual goals between treatment and parole agencies, implementing a recovery-oriented system of care (coordinated system of community supports based on person-centred care), using professional associations to disseminate policy statements, and providing cross-training on OAT.89

Limitations

The findings of this Environmental Scan aim to present a broad overview of opioid programs both across Canada and internationally and based on a survey and limited literature review. It therefore may not provide a fully comprehensive review of the topic. There may be opioid programs across Canada that are not well-documented either in the literature or online, and therefore were not captured in this report.

Methods

The quality of included studies is uncertain because of the lack of critical appraisal of the literature and the broad inclusion of publication types. In addition, the literature screening and data abstraction was not performed in duplicate. Surveys were sent to stakeholders identified by the ISKM team at CADTH. With the substantial number of opioid programs and opioid addictions within Canada, it is likely that some potential stakeholders suitable for this report were not contacted. This could potentially create a gap in valuable information regarding opioid treatment.

Survey Results

Although there was representation from numerous jurisdictions and settings captured in the survey results, not all jurisdictions responded to the survey. As well, respondents were only able to speak on behalf of their own program and may not have been able to comment on other programs. The responses to the survey also reflect personal experiences with opioid programming in Canada and may not reflect all programming within that jurisdiction. The total response rate was 26.3%, with 2.7% of asked stakeholders declining participation and the remainder not providing any responses.

Additionally, only providers of care for opioid treatment were contacted to provide survey responses. No patients or individuals with experience within the system were contacted, although these experiences and perspectives would potentially be relevant.

Literature

Specific literature and information regarding entry criteria and prioritization of recipients of opioid treatment was lacking. Given that the scope was restricted to international addiction programs in countries with similarities to the Canadian context, this report does not highlight all opioid programming in all countries. Finally, some insights from other countries may not be generalizable to the Canadian context, and some insights from some provinces and territories may not apply to other provinces and territories because of differing provincial health care systems and populations.

Conclusions and Implications for Decision- or Policy-Making

This Environmental Scan was informed by literature searches and a survey. Seventeen full responses were collected from the survey, resulting in a response rate of 26.3%. Although limited by number and type of respondents, survey responses were generally in-depth and informative.

There are numerous types of opioid programs both in Canada and internationally, including residential treatment, community treatment, primary care, pharmacy treatment, therapeutic communities, and programs within prison or jail settings. The most common type of programs use a combination of OAT, such as methadone or buprenorphine, and psychosocial treatments, such as counselling, therapy, and housing support.

Wait times for many programs in Canada were reported to average between zero and two weeks, although timing may vary between jurisdictions, urban and rural areas, and between correctional settings and public care. Literature results did not always align with the survey results; however, some literature was published a few years earlier than the survey and may not accurately reflect current wait times. Additionally, with the limited number of programs captured by the survey, programs with varying wait times may not have been captured in this report. Timely access to treatment can be achieved through limiting barriers to treatment and providing rapid access to clinics, such as through RAAM clinics and integration of care. Streamlined assessments and screening are also potential options for enabling timely access to opioid treatments within Canada. Major barriers to opioid care include a lack of addiction services, stigma and judgment, long wait times, strict entry criteria, expensive private services, and a limited number of providers of care. Additionally, structural barriers such as public opposition to harms reduction efforts and far travel times to clinics create obstacles to care for patients with addictions.

Most services appear to accept patients who have a DSM-V diagnosed substance use disorder with not many other restrictions. Common prioritization criteria for services include patients who are high risk, such as pregnant patients, adolescents, and individuals with HIV. It was reported in the literature that, across the continuum of care, patients should determine the goal of treatment, be engaged with treatment, and collaborate in the treatment plan. The literature also reported that recovery-oriented systems of care can be used and that stigma should be reduced. To ensure the continuity of care during transitions to other settings, warm hand-offs can be used, as well as the integration of care to promote seamless transitions.

References

  1. About opioids. Ottawa (ON): Health Canada; 2019: https://www.canada.ca/en/health-canada/services/substance-use/problematic-prescription-drug-use/opioids/about.html?utm_source=Youtube&utm_medium=Video&utm_campaign=EOACOpioidsCreative2&utm_term=Opioids. Accessed 2019 May 17.
  2. Addiction. Toronto (ON): Centre for Addiction and Mental Health (CAMH); 2019: https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/addiction Accessed 2019 May 17.
  3. Narcotic drugs: Estimated world requirements for 2013 - Statistics for 2011. Vienna (AT): International Narcotics Control Board (INCB); 2013: https://www.incb.org/documents/Narcotic-Drugs/Technical-Publications/2012/Narcotic_Drugs_Report_2012.pdf. Accessed 2019 May 17.
  4. National report: Apparent opioid-related deaths in Canada. Ottawa (ON): Government of Canada; 2019: https://infobase.phac-aspc.gc.ca/datalab/national-surveillance-opioid-mortality.html. Accessed 2019 May 17.
  5. Opioid agonist therapy. Toronto (ON): Centre for Addiction and Mental Health (CAMH); 2016: https://www.camh.ca/-/media/files/oat-info-for-clients.pdf Accessed 2019 May 17.
  6. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva (CH): World Health Organization (WHO); 2009: https://apps.who.int/iris/bitstream/handle/10665/43948/9789241547543_eng.pdf;jsessionid=422AE312E9DE131132DBC9BA9DF401A7?sequence=1. Accessed 2019 May 17.
  7. Best practices across the continuum of care for the treatment of opioid use disorder. Ottawa (ON): Canadian Centre on Substance Use and Addiction (CCSA); 2018: https://www.ccsa.ca/best-practices-across-continuum-care-treatment-opioid-use-disorder. Accessed 2019 May 17.
  8. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What actually works? A systematic review. PloS one. 2017;12(10):e0186315.
  9. CRISM national guideline for the clinical management of opioid use disorder. The Canadian Research Initiative in Substance Misuse; 2018: https://crism.ca/wp-content/uploads/2018/03/CRISM_NationalGuideline_OUD-ENG.pdf. Accessed 2019 May 17.
  10. Evidence on topics related to prescription drug abuse [Evidence Bundle]. Ottawa (ON): CADTH; 2019: https://cadth.ca/evidence-bundles/evidence-topics-related-prescription-drug-abuse. Accessed 2019 June 24.
  11. Directory of mental health and addictions services in Saskatchewan. Regina (SK): Government of Saskatchewan,; 2018: http://publications.gov.sk.ca/documents/13/106350-MHA-Services-Directory-Saskatchewan-2018.pdf Accessed 2019 May 17.
  12. Eibl JK, Morin K, Leinonen E, Marsh DC. The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight. Can J Psychiatry. 2017;62(7):444-450.
  13. Methadone program. Ottawa (ON): Health Canada; 2017: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/exemptions/methadone-program.html Accessed 2019 May 17.
  14. Methadone maintenance treatment handbook. Halifax (NS): College of Physicians and Surgeons of Nova Scotia; 2017: https://cpsns.ns.ca/wp-content/uploads/2017/10/Methadone-Maintenance-Treatment-Handbook.pdf. Accessed 2019 May 17.
  15. Goss Gilroy Inc. Report of the gaps analysis for opioid dependence treatment (ODT) in Newfoundland and Labrador. St. John's (NL): Government of Newfoundland and Labrador - Department of Health and Community Services; 2017: https://www.health.gov.nl.ca/health/publications/pdf/ODT_gaps_analysis_Report.pdf Accessed 2019 May 17.
  16. Opioid treatment and naloxone. St. John's (NL): Government of Newfoundland and Labrador - Eastern Health; 2018: http://www.easternhealth.ca/WebInWeb.aspx?d=2&id=2458&p=2106. Accessed 2019 May 17.
  17. Socias ME, Wood E, Kerr T, et al. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016. Drug Alcohol Depend. 2018;189:90-95.
  18. Supporting safe & accessible clinical care. Edmonton (AB): College of Physicians and Surgeons of Alberta: http://www.cpsa.ca/physician-prescribing-practices/methadone-program/?highlight=opioid%20agonist Accessed 2019 May 17.
  19. Eibl JK, Gomes T, Martins D, et al. Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada. J Addict Med. 2015;9(6):440-446.
  20. Rapid access to addictions medicine (RAAM) clinic. Winnipeg (MB): Winnipeg Regional Health Authority; 2019: http://www.wrha.mb.ca/prog/mentalhealth/raam.php. Accessed 2019 June 25.
  21. Poulin G. Opioids agonist treatment in Manitoba. Winnipeg (MB): College of Pharmacists of Manitoba; 2017: https://www.cphm.ca/uploaded/web/Professional%20Development/Opioid%20Spectrum/Opioids%20Agonist%20Treatment%20in%20Manitoba.pdf. Accessed 2019 May 17.
  22. The Potential Group for the Toronto Central LHIN. Access and integration - Transforming pathways for services for substance use and addictions: Report and recommendations from the Community Strategy Initiative October 2014 – April 2015. Toronto (ON): Ontario Local Health Integration Network; 2015. Accessed 2019 May 17.
  23. Mamakwa S, Kahan M, Kanate D, et al. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study. Can Fam Physician. 2017;63(2):137-145.
  24. Russell C, Firestone M, Kelly L, Mushquash C, Fischer B. Prescription opioid prescribing, use/misuse, harms and treatment among Aboriginal people in Canada: a narrative review of available data and indicators. Rural Remote Health. 2016;16(4):3974.
  25. NVision Insight Group Inc. Addictions and trauma treatment in Nunavut: Executive summary. Iqaluit (NU): Government of Nunavut; 2018: https://www.gov.nu.ca/sites/default/files/gn_att_executive_summary_summary_report_-_final_-_english.pdf. Accessed 2019 May 17.
  26. Overdose emergency response centre: Terms of reference. Victoria (BC): Government of British Columbia; 2017: https://www2.gov.bc.ca/assets/gov/overdose-awareness/terms_of_reference_nov_30_final.pdf Accessed 2019 May 17.
  27. Government of Northwest Territories. Opioid maintenance therapy based in Yellowknife. 2019; https://www.hss.gov.nt.ca/en/services/opioid-overdose-prevention/opioid-maintenance-therapy-yellowknife. Accessed 2019 May 17.
  28. Naloxone kit distribution sites. St. John's (NL): Government of Newfoundland and Labrador - Department of Health and Community Services; 2018: www.health.gov.nl.ca/health/naloxonekits/. Accessed 2019 May 17.
  29. Supervised injection sites. Montreal (QC): Sante Montreal; 2019: https://santemontreal.qc.ca/en/public/support-and-services/supervised-injection-services/ Accessed 2019 May 17.
  30. Substance use/addiction. St. John's (NL): Bridge the gApp; 2019: https://www.bridgethegapp.ca/adult/service-directory/service_directory_tag/substance-use-addiction/ Accessed 2019 May 17.
  31. Livingston JD, Adams E, Jordan M, MacMillan Z, Hering R. Primary Care Physicians' Views about Prescribing Methadone to Treat Opioid Use Disorder. Substance Use & Misuse. 2018;53(2):344-353.
  32. Yukon's opioid action plan. Whitehorse (YT): Government of Yukon - Health and Social Services; 2018: https://yukon.ca/sites/yukon.ca/files/hss/hss-yukon-opioid-action.pdf. Accessed 2019 May 17.
  33. McIntyre JL. Combatting the Opioid Crisis From Prison: Initiating Opioid Agonist Therapy. J. 2018;14(4):248-252.
  34. Moore G. Modern medicine: New rapid access treatment helps more than 200 opioid addicts. Toronto (ON): CBC/Radio-Canada; 2017: https://www.cbc.ca/news/canada/newfoundland-labrador/doctor-uses-telemedicine-treats-opioid-addicts-1.4240392. Accessed 2019 May 17.
  35. Opioid Addiction Resources in Alberta. Expert care, close to home, Virtual Opioid Dependency Program (VODP). Treatment for opioid addiction. 2017;,. Available at: https://opioidrecoveryalberta.ca/vodp. Accessed 2019 May 17.
  36. Focus on harm reduction for injection drug use in Canadian prisons: A supplement to CNA's harm reduction discussion paper Ottawa (ON): Canadian Nurses' Association; 2017: https://cna-aiic.ca/-/media/cna/page-content/pdf-en/cna-harm-reduction-in-canadas-prisons-a-companion-document.pdf?la=en&hash=DA0F1AA67F868820FF5FD00608AC8E44EBDB816C Accessed 2019 May 17.
  37. Correctional Service Canada announces a prison needle exchange program [News release]. Toronto (ON): Cision Canada; 2018: https://www.newswire.ca/news-releases/correctional-service-canada-announces-a-prison-needle-exchange-program-682556901.html. Accessed 2019 May 17.
  38. Drug treatment court funding program evaluation. Ottawa (ON): Government of Canada - Department of Justice; 2017: https://justice.gc.ca/eng/rp-pr/cp-pm/eval/rep-rap/2015/dtcfp-pfttt/p8.html. Accessed 2019 May 17.
  39. Fischer B, Murphy Y, Rudzinski K, MacPherson D. Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. Int J Drug Policy. 2016;27:23-35.
  40. Drug treatment courts (Chapter 6.1). Public Prosecution Service of Canada Deskbook. Ottawa (ON): Government of Canada - Department of Justice; 2014: https://ppsc-sppc.gc.ca/eng/pub/fpsd-sfpg/fps-sfp/tpd/p6/ch01.html. Accessed 2019 May 17.
  41. Brady KT, McCauley JL, Back SE. Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update. Am J Psychiatry. 2016;173(1):18-26.
  42. Federal guidelines for opioid treatment programs. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2015: https://store.samhsa.gov/system/files/pep15-fedguideotp.pdf. Accessed 2019 May 17.
  43. McElrath K. Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary. Substance Use & Misuse. 2018;53(2):334-343.
  44. Medication and counseling treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2019: https://www.samhsa.gov/medication-assisted-treatment/treatment. Accessed 2019 May 17.
  45. Buprenorphine practitioner locator. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2019: https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator. Accessed 2019 May 17.
  46. Opioid treatment program directory. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2019: https://dpt2.samhsa.gov/treatment/directory.aspx. Accessed 2019 May 17.
  47. Parrino MW, Maremmani AG, Samuels PN, Maremmani I. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World. J Addict Dis. 2015;34(2-3):255-262.
  48. Reynolds V, Causey H, McKee J, Reinstein V, Muzyk A. The Role of Pharmacists in the Opioid Epidemic: An Examination of Pharmacist-Focused Initiatives Across the United States and North Carolina. N C Med J. 2017;78(3):202-205.
  49. Company overview of emocha Mobile Health Inc.: Bloomberg L.P.; 2019: https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=264122142. Accessed 2019 June 24.
  50. m-Health applications for responding to drug use and associated harms. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2018: http://www.emcdda.europa.eu/system/files/publications/10244/EMCDDA%20Papers_m-Health%20applications_Final.pdf. Accessed 2019 May 17.
  51. Mobile apps. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2019: https://store.samhsa.gov/apps/mat/index.html?WT.ac=AD_20161021_MATx.
  52. Chaar BB, Wang H, Day CA, Hanrahan JR, Winstock AR, Fois R. Factors influencing pharmacy services in opioid substitution treatment. Drug Alcohol Rev. 2013;32(4):426-434.
  53. Kovitwanichkanont T, Day CA. Prescription Opioid Misuse and Public Health Approach in Australia. Substance Use & Misuse. 2018;53(2):200-205.
  54. Deering D, Sellman JD, Adamson S. Opioid substitution treatment in New Zealand: a 40 year perspective. N Z Med J. 2014;127(1397):57-66.
  55. New Zealand practice guidelines for opioid substitution treatment. Wellington (NZ): Government of New Zealand; 2014: https://baynav.bopdhb.govt.nz/media/1461/nz-practice-guidelines-opioid-substitution-treatment-apr14.pdf Accessed 2019 May 17.
  56. European drug report 2018: Trends and developments. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2018: http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf. Accessed 2019 May 17.
  57. Greece country drug report. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2018: http://www.emcdda.europa.eu/countries/drug-reports/2018/greece/treatment_en Accessed 2019 May 17.
  58. Health and social responses to drug problems. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2017: http://www.emcdda.europa.eu/system/files/publications/6343/TI_PUBPDF_TD0117699ENN_PDFWEB_20171009153649.pdf Accessed 2019 May 17.
  59. UK country drug report. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2018: http://www.emcdda.europa.eu/countries/drug-reports/2018/united-kingdom_en. Accessed 2019 May 17.
  60. Polomeni P, Schwan R. Management of opioid addiction with buprenorphine: French history and current management. Int J Gen Med. 2014;7:143-148.
  61. Roux P, Lions C, Carrieri MP. Increasing access to opioid maintenance treatment: the role of primary care in France. Int J Drug Policy. 2015;26(4):434-435.
  62. France country drug report. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction,; 2019: http://www.emcdda.europa.eu/countries/drug-reports/2019/france/treatment_en. Accessed 2019 June 24.
  63. Spain country drug report. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2018: http://www.emcdda.europa.eu/countries/drug-reports/2018/spain/treatment_en Accessed 2019 May 17.
  64. Torrens M, Fonseca F, Castillo C, Domingo-Salvany A. Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bull World Health Organ. 2013;91(2):136-141.
  65. Sander G, Scandurra A, Kamenska A, et al. Overview of harm reduction in prisons in seven European countries. Harm Reduct J. 2016;13(1):28.
  66. About us. Athens (GR): (Organisation Against Drugs) Okana: https://www.okana.gr/2012-04-03-07-49-40/item/253-about-us Accessed 2019 May 17.
  67. Treatment programmes. Athens (GR): Kethea; 2018: https://www.kethea.gr/en/kethea/therapeutic-programmes/. Accessed 2019 May 17.
  68. Italy country drug report. Lisbon (PT): European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2018: http://www.emcdda.europa.eu/countries/drug-reports/2018/italy_en. Accessed 2019 May 17.
  69. Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.
  70. AHS report on performance FY 2017-18: Wait time for addiction outpatient treatment (in days). Edmonton (AB): Alberta Health Services (AHS); 2018: https://www.albertahealthservices.ca/assets/about/publications/ahs-pub-pr-2017-18-q4-objective-04.pdf. Accessed 2019 May 17.
  71. Opioid use disorder: Care for people 16 years of age and older [Quality standards]. Toronto (ON): Health Quality Ontario: http://www.hqontario.ca/portals/0/documents/evidence/quality-standards/qs-opioid-use-disorder-clinician-guide-en.pdf. Accessed 2019 May 17.
  72. Recommendations for adoption: Opioid use disorder. Recommendations to enable widespread adoption of this quality standard. Toronto (ON): Health Quality Ontario; 2018: https://www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-opioid-use-disorder-recommendations-for-adoption-en.pdf. Accessed 2019 May 17.
  73. Taking stock: A report on the quality of mental health and addictions services in Ontario. Toronto (ON): Health Quality Ontario; 2015: https://www.hqontario.ca/Portals/0/Documents/pr/theme-report-taking-stock-en.pdf Accessed 2019 May 17.
  74. Opioid assessment clinic. Winnipeg (MB): Health Sciences Centre; 2018: https://cpsm.mb.ca/cjj39alckF30a/wp-content/uploads/Opioid%20Assessment%20Clinic.pdf. Accessed 2019 May 17.
  75. Bozinoff N, DeBeck K, Milloy MJ, et al. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada. Drug Alcohol Depend. 2018;193:42-47.
  76. Care not corrections: Relieving the opioid crisis in Canada. Toronto (ON): Canadian Mental Health Association; 2018: https://cmha.ca/wp-content/uploads/2018/04/CMHA-Opioid-Policy-Full-Report_Final_EN.pdf. Accessed 2019 May 17.
  77. Kouyoumdjian FG, Patel A, To MJ, Kiefer L, Regenstreif L. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey. PLoS ONE [Electronic Resource]. 2018;13(2):e0192431.
  78. Opioid Addiction Resources Alberta. Welcome to opioid addiction resources Alberta. 2017; https://opioidrecoveryalberta.ca/. Accessed 2019 May 17.
  79. Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014. Jama, Pediatr. 2017;171(8):747-755.
  80. Opioids and addiction: A primer for journalists. Toronto (ON): CAMH,; 2016: http://www.camh.ca/-/media/files/5217-opdsaddic_primer-pdf.pdf. Accessed 2019 June 24.
  81. Socias ME, Ahamad K. An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders. Cmaj. 2016;188(17-18):1208-1209.
  82. A guideline for the clinical management of opioid use disorder. Vancouver (BC): British Columbia Centre on Substance Use; 2017: http://www.bccsu.ca/wp-content/uploads/2017/06/BC-OUD-Guidelines_June2017.pdf. Accessed 2019 May 17.
  83. Bernstein SE, Bennett D. Zoned Out: "NIMBYism", addiction services and municipal governance in British Columbia. Int J Drug Policy. 2013;24(6):e61-65.
  84. Methadone Treatment and Services Advisory Committee: Final Report. Toronto (ON): Government of Ontario - Ministry of Health and Long-Term Care; 2016: http://health.gov.on.ca/en/public/programs/drugs/ons/docs/methadone_advisory_committee_report.pdf. Accessed 2019 May 17.
  85. Implementation quick start guide: Warm handoff. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2017: https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-family-engagement/pfeprimarycare/warm-handoff-qsg-brochure.pdf Accessed 2019 May 17.
  86. Miles B. 'Warm Handoff' program seeks to close treatment gap for opioid users. Chicago (IL): NPR - WBEZ Chicago; 2019: https://www.npr.org/local/309/2019/04/25/716563198/warm-handoff-program-seeks-to-close-treatment-gap-for-opioid-users. Accessed 2019 May 17.
  87. Warm hand-off care map. Government of Pennsylvania - Department of Drug and Alcohol Programs; 2018: https://www.ddap.pa.gov/Documents/Agency%20Publications/Warm%20Hand-Off/Warm%20Hand-off%20Care%20Map.pdf Accessed 2019 May 17.
  88. Guidelines for successful transition of people with mental or substance use disorders from jail and prison: Implementation guide. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2017: https://store.samhsa.gov/system/files/sma16-4998.pdf. Accessed 2019 May 17.
  89. Welsh WN, Knudsen HK, Knight K, et al. Effects of an Organizational Linkage Intervention on Inter-Organizational Service Coordination Between Probation/Parole Agencies and Community Treatment Providers. Adm Policy Ment Health. 2016;43(1):105-121.
  90. Investments expand opioid addiction treatment. Charlottetown (PE): Government of Prince Edward Island; 2019: https://www.princeedwardisland.ca/en/news/investments-expand-opioid-addiction-treatment Accessed 2019 May 17.
  91. Integrated correctional program model. Ottawa (ON): Correctional Service Canada; 2014: https://www.csc-scc.gc.ca/correctional-process/002001-2011-eng.shtml Accessed 2019 May 17.
  92. Correctional Service Canada. National substance abuse programs. Ottawa (ON): Correctional Service Canada; 2014: https://www.csc-scc.gc.ca/correctional-process/002001-2009-eng.shtml. Accessed 2019 May 17.
  93. TDTC program flow chart. Etobicoke (ON): Toronto Drug Treatment Court; 2016: https://www.tdtc.ca/sites/default/files/pages/TDTC%20Treatment%20Model%20Flow%20Chart.pdf. Accessed 2019 May 17.
  94. Fu JJ, Zaller ND, Yokell MA, Bazazi AR, Rich JD. Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. J Subst Abuse Treat. 2013;44(5):502-505.
  95. Dolan K, Rodas A, Bode A. Drug and alcohol use and treatment for Australian Indigenous and non-Indigenous prisoners: demand reduction strategies. Int J Prison Health. 2015;11(1):30-38.

Appendices

Appendices

About This Document

Authors: Charlotte Wells, Bert Dolcine, Nina Frey

Acknowledgement: Camille Dulong

Cite As: Programs for the Treatment of Opioid Addiction: An Environmental Scan. Ottawa: CADTH; 2019. (Environmental scan; no. 87).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the materialwas first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

Contact requests@cadth.ca with inquiries about this notice or legal matters relating to CADTH services.